

Experimental Zika vaccine to begin human testing

June 20 2016, by Matthew Perrone



In this Feb. 11, 2016 file photo of aedes aegypti mosquitoes are seen in a mosquito cage at a laboratory in Cucuta, Colombia. An experimental vaccine for the Zika virus is due to begin human testing in coming weeks, after getting the green light from U.S. health officials. Inovio Pharmaceuticals said Monday, June 20, 2016, that it received clearance from the Food and Drug Administration to begin early-stage safety tests of its DNA-based vaccine against the mosquito-borne virus.(AP Photo/Ricardo Mazalan, File)

An experimental vaccine for the Zika virus is due to begin human testing



in coming weeks, after getting the green light from U.S. health officials.

Inovio Pharmaceuticals said Monday it received clearance from the Food and Drug Administration to begin early-stage safety tests of its DNA-based vaccine against the mosquito-borne virus. That puts the company ahead of researchers at the National Institutes of Health, who have said they expect to begin testing their own DNA-based Zika vaccine by early fall.

Inovio's vaccine is intended to prime the immune system to fight Zika by introducing genetically-engineered material that mimics the virus. Inovio reports that animals tested with the vaccine developed antibodies and immune-system cells that attack Zika.

The NIH is working to develop a Zika vaccine by swapping out the genetic material from its experimental West Nile virus vaccine.

Inovio and its partner, GeneOne Life Science, plan to begin a 40-person study to determine the safest dose of the vaccine in coming weeks. Company officials said they expect results from the <u>vaccine</u> study by the end of 2016.

There are currently no licensed drugs or vaccines for Zika.

Ultimately, confirming the safety and effectiveness of any Zika <u>virus</u> will require large studies, and how fast those could be done depends in part on whether Zika still is spreading widely in 2017.

Zika is spread mainly through the bite of a tropical mosquito, Aedes aegypti. It causes only a mild and brief illness, at worst, in most people. But it can cause fetal deaths and severe birth defects in the children of women infected during pregnancy.



Zika has become epidemic in Latin America and the Caribbean since last fall. Officials aren't expecting big outbreaks in the continental U.S., but some cases are likely as temperatures rise and mosquitoes spread.

Shares of Plymouth Meeting, Pennsylvania-based Inovio jumped 29 cents, or 2.8 percent, to \$10.76 in midday trading Monday.

© 2016 The Associated Press. All rights reserved.

Citation: Experimental Zika vaccine to begin human testing (2016, June 20) retrieved 23 November 2023 from <u>https://medicalxpress.com/news/2016-06-experimental-zika-vaccine-human.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.